A landscape of driver mutations in melanoma

Hodis, Eran, Watson, Ian R., Kryukov, Gregory V., Arold, Stefan T., Imielinski, Marcin, Theurillat, Jean-Philippe, Nickerson, Elizabeth, Auclair, Daniel +32 more·2012·Cell
DOI 10.1016/j.cell.2012.06.024

Cited by (1,006)

Items 801–900 of 1,006

  1. Rho-Family Small GTPases: From Highly Polarized Sensory Neurons to Cancer Cells
    Takehiko Ueyama · 2019 · Cells
  2. FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation
    Cheol‐Jung Lee, Hyun‐Jung An, Seung Min Kim, Sun-Mi Yoo, Juhee Park, Ga-Eun Lee, Woo‐Young Kim, Dae Joon Kim, Han Chang Kang, Joo Young Lee et al. · 2019 · Proceedings of the National Academy of Sciences
  3. Systematic functional identification of cancer multi-drug resistance genes
    Man-Tat Lau, Shila Ghazanfar, Ashleigh Parkin, Angela S. Y. Chou, Jourdin R.C. Rouaen, Jamie B. Littleboy, Danielle Nessem, Thang M. Khuong, Damien Névoltris, Peter Schofield et al. · 2020 · Genome biology
  4. Integrated molecular drivers coordinate biological and clinical states in melanoma
    Jake R. Conway, Felix Dietlein, Amaro N Taylor-Weiner, Saud H. AlDubayan, Natalie I. Vokes, Tanya Elizabeth Keenan, Brendan Michael Reardon, Meng Xiao He, Claire A. Margolis, Jason L. Weirather et al. · 2020 · Nature Genetics
  5. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy
    Tomasz Witold Radaszkiewicz, Michaela Nosková, Kristína Gömöryová, Olga Vondálová Blanářová, Katarzyna Anna Radaszkiewicz, Markéta Pícková, Ráchel Víchová, Tomáš Gybeľ, Karol Kaiser, Lucia Demková et al. · 2021 · eLife
  6. Solar ultraviolet‐induced DNA damage response: Melanocytes story in transformation to environmental melanomagenesis
    Soumyadeep Sarkar, Shobhan Gaddameedhi · 2020 · Environmental and Molecular Mutagenesis
  7. The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target
    Sophie M. Navickas, Katherine A. Giles, Kate H. Brettingham‐Moore, Phillippa C. Taberlay · 2023 · Oncogene
  8. Targeting p53 in melanoma
    Neil F. Box, Tyler O. Vukmer, Tamara Terzian · 2013 · Pigment Cell & Melanoma Research
  9. The landscape of precision cancer medicine clinical trials in the United States
    Nitin Roper, Kristian Donald Stensland, Ryan Hendricks, Matthew D. Galsky · 2015 · Cancer Treatment Reviews
  10. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review
    Douglas Buckner Johnson, Chengwei Peng, Richard Glenn Abramson, Fei Ye, Shilin Zhao, Jedd D. Wolchok, Jeffrey Alan Sosman, Richard D. Carvajal, Charlotte Eielson Ariyan · 2015 · The Oncologist
  11. Characteristics, rates, and trends of melanoma incidence among Hispanics in the USA
    Erin Garnett, Julie S. Townsend, Brooke Steele, Meg Watson · 2016 · Cancer Causes & Control
  12. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
    Hani M. Babiker, Irbaz Bin Riaz, Muhammad Husnain, Mitesh J. Borad · 2017 · Oncolytic Virotherapy
  13. Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide
    Albin Jeanne, Valérie Untereiner, Corinne Perreau, Isabelle Proult, Cyril Gobinet, Camille Boulagnon‐Rombi, Christine Terryn, Laurent Martiny, Stéphane Brézillon, Stéphane Dedieu · 2017 · Scientific Reports
  14. Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma
    Filipe V. Almeida, Stephen M. Douglass, Mitchell E. Fane, Ashani T. Weeraratna · 2018 · Pigment Cell & Melanoma Research
  15. PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
    Kristen Suzanne Hill, Evan R. Roberts, Xue Wang, Ellen M. Marin, Taeeun D. Park, Sorany Son, Yuan Ren, Bin Fang, Sean Yoder, Sungjune Kim et al. · 2018 · Molecular Cancer Research
  16. Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
    Fatima Bilal, Anne Montfort, Julia Gilhodes, Virginie Garcia, Joëlle Riond, Stéphane Carpentier, Thomas Filleron, Céline Colacios, Thierry Levade, Ahmad Daher et al. · 2019 · Frontiers in Pharmacology
  17. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4
    Yan Mo, Shoufu Duan, Xu Zhang, Xu Hua, Hui Zhou, Hong-Jian Wei, Jun Watanabe, Nicholas McQuillan, Zhenyi Su, Wei Jun Gu et al. · 2022 · Cancer Discovery
  18. Cellular adaptation to nutrient deprivation: crosstalk between the mTORC1 and eIF2α signaling pathways and implications for autophagy
    Jordan Wengrod, Lawrence B. Gardner · 2015 · Cell Cycle
  19. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma
    Katharine J. Herbert, Romuald Binet, Jean‐Philippe Lambert, Pakavarin Louphrasitthiphol, Halime Kalkavan, Laura Sesma-Sanz, Carla Daniela Robles‐Espinoza, Sovan Sarkar, Eda Suer, Sarah Andrews et al. · 2019 · Genes & Development
  20. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response
    Israel S. Kasago, Walid Khaled Chatila, Cecilia M. Lezcano, Christopher A. Febres‐Aldana, Nikolaus D. Schultz, Chad Vanderbilt, Snjezana Doğan, Edmund K. Bartlett, Sandra P. D’Angelo, William D. Tap et al. · 2023 · Modern Pathology
  21. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
    Maicol Mancini, Yosef Yarden · 2015 · Seminars in Cell and Developmental Biology
  22. The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models
    Jennifer L. Yen, Richard Mark White, David C. Wedge, Peter Van Loo, Jeroen de Ridder, Amy Capper, Jennifer Richardson, David Jones, Keiran M. Raine, Ian R. Watson et al. · 2013 · Genome biology
  23. Biology and treatment of BRAF mutant metastatic melanoma.
    B. Kong, M. Carlino, A. Menzies · 2016 · Melanoma Management
  24. Targeting invasive properties of melanoma cells
    Imanol Arozarena, Claudia Wellbrock · 2017 · FEBS Journal
  25. How many melanomas might be prevented if more people applied sunscreen regularly?
    Catherine M. Olsen, Louise Forsyth Wilson, Adèle C. Green, Neela Biswas, J. Loyalka, David C. Whiteman · 2017 · British Journal of Dermatology
  26. SUV39H1/DNMT3A‐dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development
    Garam Kim, Jinyoung Kim, Sung‐Chul Lim, Kwang Youl Lee, Okyun Kim, Hong Seok Choi · 2018 · The FASEB Journal
  27. RHO Family GTPases in the Biology of Lymphoma
    Claudia Voena, Roberto Chiarle · 2019 · Cells
  28. DNA Sequencing Technologies
    Ka‐Chun Wong, Jiao Zhang, Shankai Yan, Xiangtao Li, Qiuzhen Lin, Sam Kwong, Cheng Liang · 2019 · ACM Computing Surveys
  29. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
    Amy Lauren Cummings, Jaklin Gukasyan, Henry Y. Lu, Tristan Grogan, Gemalene M. Sunga, Charlene Marie Fares, Nicholas J. Hornstein, Jesse Meir Zaretsky, James Carroll, Benjamin Bachrach et al. · 2020 · Nature Cancer
  30. Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring
    Paula Kamińska, Karolina Buszka, Maciej Zabel, Michal O. Nowicki, Catherine Alix‐Panabières, Joanna Budna · 2021 · International Journal of Molecular Sciences
  31. The Centrosomal Adaptor TACC3 and the Microtubule Polymerase chTOG Interact via Defined C-terminal Subdomains in an Aurora-A Kinase-independent Manner
    Harish C. Thakur, Madhurendra Singh, Luitgard Nagel‐Steger, Jana Kremer, Daniel Prumbaum, Eyad K. Fansa, Hakima Ezzahoini, Kazem Nouri, Lothar Gremer, André Abts et al. · 2013 · Journal of Biological Chemistry
  32. Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells
    Daniel Eduardo Gomez, Georgina Alexandra Cardama, Nazareno González, Matias S Ciarlantini, Maria Julieta Comin, Daniel F. Alonso, Pablo Lorenzano Menna, Lucía Gandolfi Donadio · 2014 · OncoTargets and Therapy
  33. Molecular Networks in Melanoma Invasion and Metastasis
    Ewa Aładowicz, Leda Ferro, Giulio Cesare Vitali, Elisabetta Venditti, Lorenzo Fornasari, Luisa Lanfrancone · 2013 · Future Oncology
  34. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon‐V600 mutations in cutaneous melanoma patients
    Dae Won Kim, Lauren Elaine Haydu, Aron Y. Joon, Roland L. Bassett, Alan E. Siroy, Michael T. Tetzlaff, Mark J. Routbort, Rodabe Navroze Amaria, Jennifer Ann Wargo, Jennifer Leigh McQuade et al. · 2016 · Cancer
  35. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition
    Kathy Ann Gelato, Laura Schöckel, Olaf Klingbeil, Timo Rückert, Ralf Lesche, Joern Toedling, E Kalfon, Mélanie Héroult, Pascale Lejeune, U. Mönning et al. · 2017 · Oncogene
  36. Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NF‑κB and PI3K/Akt signaling pathways
    Zhichao Liao, Jun Li Zhao, Yun Yang · 2018 · Molecular Medicine Reports
  37. Two critical positions in zinc finger domains are heavily mutated in three human cancer types
    Daniel B. Munro, Dario Ghersi, Mona Singh · 2018 · PLoS Computational Biology
  38. Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy
    Paola Marino Dantônio, Marianne Klein, Maria Renata Valente Brandão Freire, Camila do Nascimento Araujo, Ana Carolina Chiacetti, Ricardo G. Correa · 2018 · Bioscience Reports
  39. Structural snapshots of RAF kinase interactions
    Soheila Rezaei Adariani, Marcel Buchholzer, Mohammad Akbarzadeh, Saeideh Nakhaei‐Rad, Radovan Dvorský, Mohammad Reza Ahmadian · 2018 · Biochemical Society Transactions
  40. Interplay between small and long non‐coding RNA s in cutaneous melanoma: a complex jigsaw puzzle with missing pieces
    Mattia Riefolo, Elisa Porcellini, Emi Dika, Elisabetta Broseghini, Manuela Ferracin · 2018 · Molecular Oncology
  41. Thymine DNA glycosylase as a novel target for melanoma
    Pietro Mancuso, Rossella Tricarico, Vikram Bhattacharjee, Laura Cosentino, Yuwaraj Kadariya, Jaroslav Jelı́nek, Émmanuelle Nicolas, Margret B. Einarson, Neil Beeharry, Karthik Devarajan et al. · 2019 · Oncogene
  42. The stressful tumour environment drives plasticity of cell migration programmes, contributing to metastasis
    Savvas Nikolaou, Laura M. Machesky · 2020 · The Journal of Pathology
  43. CELLector: Genomics-Guided Selection of Cancer In Vitro Models
    Hanna Najgebauer, Mi Yang, Hayley E. Francies, Clare Pacini, Euan A. Stronach, Mathew J. Garnett, Julio Sáez-Rodríguez, Francesco Iorio · 2020 · Cell Systems
  44. Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
    A. García-Álvarez, C. Ortiz, E. Muñoz-Couselo · 2021 · OncoTargets and Therapy
  45. Epigenetic Regulation in Melanoma: Facts and Hopes
    Emilio Francesco Giunta, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Mario Rosanova, Anna Diana, Pasqualina Giordano, Angelica Petrillo, Piera Federico et al. · 2021 · Cells
  46. Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways
    Baokang Wu, Yizhou Zhang, Yang Yu, Chongli Zhong, Qi Lang, Zhiyun Liang, Chao Lv, Feng Xu, Yu Tian · 2021 · Frontiers in Cell and Developmental Biology
  47. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
    Drew Warren Rasco, Theresa Michelle Medina, Pippa G. Corrie, Anna C. Pavlick, Mark Ross Middleton, Paul C. Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala et al. · 2023 · Cancer Chemotherapy and Pharmacology
  48. Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
    Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, Ranjan Kumar Acharyya, I. N. Chaithanya Kiran, Yesu Addepalli, V. Dhamodharan · 2024 · Pharmaceuticals
  49. HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth
    Silvia Pandolfi, Valentina Montagnani, Andrea Lapucci, Barbara A. Stecca · 2015 · Cell Death and Differentiation
  50. Reactivation of p53 as therapeutic intervention for malignant melanoma
    Aart G. Jochemsen · 2013 · Current Opinion in Oncology
  51. BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
    Luca Paoluzzi, Douglas Hanniford, Elena Sokolova, Iman Osman, Farbod Darvishian, Jinhua Wang, James E. Bradner, Eva Hernando · 2016 · Cancer Medicine
  52. Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients
    Eva Bräunlein, Angela M. Krackhardt · 2017 · Frontiers in Immunology
  53. Challenges in assessing the sunscreen‐melanoma association
    Corina S. Rueegg, Jo S Stenehjem, Matthias Egger, Reza Ghiasvand, Eunyoung Cho, Eiliv Lund, Elisabete Weiderpass, Adèle C. Green, Marit Bragelien Veierød · 2018 · International Journal of Cancer
  54. Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway
    Yongxia Zhu, Weiqiong Zuo, Lijuan Chen, Shasha Bian, Jiayu Jing, Cailin Gan, Xiuli Wu, Hongyao Liu, Xingping Su, Wanglai Hu et al. · 2019 · Biochemical Pharmacology
  55. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Patrick Schummer, Bastian Schilling, Anja Gesierich · 2020 · American Journal of Clinical Dermatology
  56. Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma
    Rached Alkallas, Mathieu Lajoie, Dan Moldoveanu, Karen Vo Hoang, Philippe Lefrançois, Marine Lingrand, Mozhdeh Ahanfeshar-Adams, Kevin A. Watters, Alan Spatz, Jonathan Hale Zippin et al. · 2020 · Nature Cancer
  57. Sunscreen applied at ≥ 2 mg cm <sup>−2</sup> during a sunny holiday prevents erythema, a biomarker of ultraviolet radiation‐induced <scp>DNA</scp> damage and suppression of acquired immunity
    Narbutt, J., Philipsen, P.A., Harrison, G.I., Morgan, K.A., Lawrence, K.P., Baczynska, K.A., Grys, K., Rogowski‐Tylman, M., Olejniczak‐Staruch, I., Tewari, A. et al. · 2019 · British Journal of Dermatology
  58. Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
    Kostas Palamaris, Myrto K. Moutafi, Hariklia Gakiopoulou, Stamatios E Theocharis · 2022 · International Journal of Molecular Sciences
  59. RHOA takes the RHOad less traveled to cancer
    Antje Schaefer, Channing J. Der · 2022 · Trends in cancer
  60. Predicting drug response from single-cell expression profiles of tumours
    Simona Pellecchia, Gaetano Viscido, Melania Franchini, Gennaro Gambardella · 2023 · BMC Medicine
  61. Trametinib in the treatment of melanoma
    R. Thota, Douglas B. Johnson, J. Sosman · 2015 · Expert Opinion on Biological Therapy
  62. Patterns and Mutational Signatures of Tandem Base Substitutions Causing Human Inherited Disease
    Jian‐Min Chen, Claude Férec, D.N. Cooper · 2013 · Human Mutation
  63. Formation of cyclobutane pyrimidine dimers at dipyrimidines containing 5-hydroxymethylcytosine
    Sang-in Kim, Seung‐Gi Jin, Gerd P. Pfeifer · 2013 · Photochemical & Photobiological Sciences
  64. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS
    Liping Zhang, Rajesh R. Singh, Keyur Pravinchandra Patel, Francesco C. Stingo, Mark J. Routbort, Mingjian James You, Roberto N. Miranda, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Leonard Jeffrey Medeiros et al. · 2014 · American Journal of Hematology
  65. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation
    Laura Barrio‐Real, Lorena Gabriela Benedetti, Nora Engel, Yaping Tu, Soonweng Cho, Saraswati V. Sukumar, Marcelo G. Kazanietz · 2014 · Breast Cancer Research
  66. PD-1 and PD-L1 Inhibitors in Melanoma Treatment: Past Success, Present Application and Future Challenges
    Jenny Lee, Richard F. Kefford, Matteo Salvatore Carlino · 2016 · Immunotherapy
  67. Structural Mechanisms and Drug Discovery Prospects of Rho GTPases
    Cameron C. Smithers, Michael Overduin · 2016 · Cells
  68. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma
    Paolo A. Ascierto, Keith T. Flaherty, Stephanie L. Goff · 2018 · American Society of Clinical Oncology Educational Book
  69. Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis
    Kumud Raj Poudel, Minna Roh‐Johnson, Xiaofeng A. Su, T. T. Giang Ho, Haritha Mathsyaraja, Sarah Anderson, William M. Grady, Cecilia B. Moens, Maralice Conacci‐Sorrell, Robert N. Eisenman et al. · 2018 · Developmental Cell
  70. Cellular senescence promotes cancer metastasis by enhancing soluble E-cadherin production
    Koichiro Kawaguchi, Kaori Komoda, Ryuta Mikawa, Azusa Asai, Masataka Sugimoto · 2021 · iScience
  71. Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma
    Monica Argenziano, Federica Bessone, Chiara Dianzani, Marie Angèle Cucci, Margherita Grattarola, Stefania Pizzimenti, Roberta Cavalli · 2022 · Pharmaceutics
  72. NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation
    Evan L. Carpenter, Alyssa L. Becker, Arup K. Indra · 2022 · Cancers
  73. NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition
    Jihan K. Osborne, Jill E. Larsen, Joshua X. Gonzales, David S. Shames, Mitsuo Sato, Ignacio Ivan Wistuba, Luc Girard, John Dorrance Minna, Melanie H. Cobb · 2013 · Oncogenesis
  74. Guanine holes are prominent targets for mutation in cancer and inherited disease
    Bacolla, Albino, Temiz, Nuri A., Yi, Ming, Ivanic, Joseph, Cer, Regina Z., Donohue, Duncan E., Ball, Edward V., Mudunuri, Uma S., Wang, Guliang, Jain, Aklank et al. · 2013 · PLoS Genetics
  75. Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma
    Saul Carcamo, Christie B. Nguyen, Elena Grossi, Dan Filipescu, Aktan Alpsoy, Alisha Dhiman, Dan Sun, Sonali Narang, Jochen Imig, Tiphaine C. Martin et al. · 2022 · Cell Reports
  76. High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
    Sho Mizuno, Masachika Ikegami, Takafumi Koyama, Kuniko Sunami, Dai Ogata, Hidenori Kage, Mitsuru Yanagaki, Hiroshi Ikeuchi, Toshihide Ueno, Michihiro Tanikawa et al. · 2022 · Molecular Cancer Therapeutics
  77. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
    Melody Riaud, Jennifer Maxwell, Isabel Soria‐Bretones, Matthew Dankner, Meredith Li, April A. N. Rose · 2024 · Nature reviews. Cancer
  78. Challenges in identifying cancer genes by analysis of exome sequencing data
    Matan Hofree, Hannah K. Carter, Jason F. Kreisberg, Sourav Bandyopadhyay, Paul S. Mischel, Stephen Henry Friend, Trey Ideker · 2016 · Nature Communications
  79. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex
    Anna de Polo, Zhongling Luo, Casimiro Gerarduzzi, Xiang Chen, John B. Little, Zhi-Min Yuan · 2016 · Journal of Molecular Cell Biology
  80. A novel unsupervised learning model for detecting driver genes from pan-cancer data through matrix tri-factorization framework with pairwise similarities constraints
    Jianing Xi, Ao Li, Minghui Wang · 2018 · Neurocomputing
  81. ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
    Chiao‐En Wu, Tsin Shue Koay, Arman Esfandiari, Yi-Hsuan Ho, Penny E. Lovat, John Lunec · 2018 · Cancers
  82. Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas
    Jarish N. Cohen, Iwei Yeh, Thaddeus W. Mully, Philip E. LeBoit, Timothy H. McCalmont · 2020 · The American Journal of Surgical Pathology
  83. Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
    Irene Vanni, Enrica T. Tanda, Bruna Dalmasso, Lorenza Pastorino, Virginia Andreotti, William Bruno, Andrea Boutros, Francesco Spagnolo, Paola Ghiorzo · 2020 · Frontiers in Molecular Biosciences
  84. ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer
    Thaidy Moreno-Rodriguez, Beatriz Monterde, Laura González-Silva, Isabel Betancor-Fernández, Carlos Revilla, Antonio Agraz-Doblás, Javier Freire, Pablo Isidro Marrón, Laura Quevedo, Rosa E. Blanco et al. · 2021 · Oncogene
  85. RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells
    Jun Sun, Gabriel Gaidosh, Ye Xu, Adnan Kasim Mookhtiar, Na Man, Pradeep Reddy Cingaram, Ezra Blumenthal, Ramin Shiekhattar, Erik T. Goka, Stephen D. Nimer et al. · 2021 · Oncogene
  86. Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patients
    Kai Zhang, Tienian Zhu, Dongmei Gao, Yimei Zhang, Qinglan Zhao, Shuang Liu, Tong-Yi Su, Michel Bernier, Ruijing Zhao · 2014 · Journal of Cancer Research and Clinical Oncology
  87. R ho J modulates melanoma invasion by altering actin cytoskeletal dynamics
    Hsiang Ho, Amelia Soto Hopkin, Rubina Kapadia, Priya Vasudeva, Jonathan Schilling, Anand K. Ganesan · 2012 · Pigment Cell & Melanoma Research
  88. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
    Martin Lauss, Markus Ringnér, Anna Karlsson, Katja Harbst, Christian Busch, Jürgen Geisler, Per Eystein Lønning, Johan Staaf, Goran B Jönsson · 2015 · BMC Medical Genomics
  89. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making
    Ricardo De Paoli‐Iseppi, Peter A. Johansson, Alexander Maxwell Menzies, Kerith‐Rae Dias, Gulietta M. Pupo, Hojabr Kakavand, James S. Wilmott, Graham J. Mann, Nicholas K. Hayward, Marcel E. Dinger et al. · 2016 · Pathology
  90. A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury
    Taiji Ishii, Takehiko Ueyama, Michiko Shigyo, Masaaki Kohta, Takeshi Kondoh, Tomoharu Kuboyama, Tatsuya Uebi, Takeshi Hamada, David H. Gutmann, Atsu Aiba et al. · 2016 · Journal of Biological Chemistry
  91. PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion
    Xianjue Ma, Jinyu Lu, Yongli Dong, Daming Li, Juan Nicolas Malagón, Tian Xu · 2017 · Cell Reports
  92. Pathways from senescence to melanoma: focus on MITF sumoylation
    J Leclerc, Robert Ballotti, Corine Bertolotto · 2017 · Oncogene
  93. Identification and functional analysis of SOX10 phosphorylation sites in melanoma
    Julia C. Cronin, Stacie K. Loftus, Laura L. Baxter, Steve Swatkoski, Marjan Guček, William J. Pavan · 2018 · PLoS ONE
  94. Loss of miR-204 expression is a key event in melanoma
    Marco Galasso, Quaid Morris, Linda Minotti, Fabio Corrà, Carlotta Zerbinati, Chiara Agnoletto, Federica Baldassari, Matteo Fassan, Armando Bartolazzi, Andrea M. Vecchione et al. · 2018 · Molecular Cancer
  95. cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage
    María Castejón-Griñán, Cecilia Herráiz, Concepción Olivares, Celia Jiménez‐Cervantes, José Carlos García-Borrón · 2018 · Oncogene
  96. Central role of autophagic UVRAG in melanogenesis and the suntan response
    Yongfei Yang, Gyu-Beom Jang, Xuanjun Yang, Qiaoxiu Wang, Shanshan He, Shun Li, Christine Quach, Shihui Zhao, Fan Li, Zengqiang Yuan et al. · 2018 · Proceedings of the National Academy of Sciences
  97. Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma
    Matilde Monti, Francesca Consoli, Raffaella Vescovi, Mattia Bugatti, William Vermi · 2020 · Cells
  98. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases
    Roy Rabbie, Naser Ansari‐Pour, Oliver M. Cast, Doreen Lau, Francis Scott, Sarah Joanne Welsh, Christine Parkinson, Leila Khoja, Luiza Moore, Mark Tullett et al. · 2020 · Nature Communications
  99. Atypical UV Photoproducts Induce Non-canonical Mutation Classes Associated with Driver Mutations in Melanoma
    Marian F. Laughery, Alexander Brown, Kaitlynne A. Bohm, Smitha Sivapragasam, Haley S. Morris, Mila Tchmola, Angelica D. Washington, Debra Mitchell, Stephen Mather, Ewa P. Malc et al. · 2020 · Cell Reports
  100. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma
    Silvia Pietrobono, Eugenio Gaudio, Sinforosa Gagliardi, Mariapaola Zitani, Laura Carrassa, Francesca Migliorini, Elena Petricci, Fabrizio Manetti, Nikolai Makukhin, Adam G. Bond et al. · 2021 · Oncogene